AU2001269821A1 - Cycloalkyl alkanoic acids as integrin receptor antagonists - Google Patents

Cycloalkyl alkanoic acids as integrin receptor antagonists

Info

Publication number
AU2001269821A1
AU2001269821A1 AU2001269821A AU6982101A AU2001269821A1 AU 2001269821 A1 AU2001269821 A1 AU 2001269821A1 AU 2001269821 A AU2001269821 A AU 2001269821A AU 6982101 A AU6982101 A AU 6982101A AU 2001269821 A1 AU2001269821 A1 AU 2001269821A1
Authority
AU
Australia
Prior art keywords
receptor antagonists
alkanoic acids
integrin receptor
cycloalkyl
cycloalkyl alkanoic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001269821A
Inventor
Barbara Chen
Michael Clare
Alan F. Gasiecki
Lu Hwang-Fun
Ish Kumar Khanna
Thomas Rogers
Mark Russel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Pharmacia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia LLC filed Critical Pharmacia LLC
Publication of AU2001269821A1 publication Critical patent/AU2001269821A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
AU2001269821A 2000-06-15 2001-06-15 Cycloalkyl alkanoic acids as integrin receptor antagonists Abandoned AU2001269821A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21178100P 2000-06-15 2000-06-15
US60/211,781 2000-06-15
PCT/US2001/019104 WO2001096307A2 (en) 2000-06-15 2001-06-15 Cycloalkyl alkanoic acids as integrin receptor antagonists

Publications (1)

Publication Number Publication Date
AU2001269821A1 true AU2001269821A1 (en) 2001-12-24

Family

ID=22788343

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001269821A Abandoned AU2001269821A1 (en) 2000-06-15 2001-06-15 Cycloalkyl alkanoic acids as integrin receptor antagonists

Country Status (8)

Country Link
US (2) US6900232B2 (en)
EP (1) EP1289960A2 (en)
JP (1) JP2004525069A (en)
AR (1) AR030701A1 (en)
AU (1) AU2001269821A1 (en)
PE (1) PE20020665A1 (en)
UY (1) UY26780A1 (en)
WO (1) WO2001096307A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6908935B2 (en) 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
US7176322B2 (en) 2002-05-23 2007-02-13 Amgen Inc. Calcium receptor modulating agents
AU2003236500B9 (en) * 2002-06-12 2009-07-02 Chemocentryx, Inc. 1-aryl-4-substituted piperazine derivatives for use as CCR1 antagonists for the treatment of inflammation and immune disorders
US7589199B2 (en) * 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
US20050256130A1 (en) * 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
US7842693B2 (en) * 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
US20040259669A1 (en) * 2003-06-20 2004-12-23 Seaway Plastics Ltd. Volleyball net pretensioned with rigid side strips
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
US7435831B2 (en) * 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
JP4845873B2 (en) * 2004-03-03 2011-12-28 ケモセントリックス インコーポレーティッド Bicyclic and bridged nitrogen heterocycles
DK1734996T3 (en) 2004-04-02 2013-06-10 Univ California METHODS AND COMPOSITIONS FOR TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH ALFA V BETA 5 INTEGRIN
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
KR101328273B1 (en) 2004-12-28 2013-11-14 키넥스 파마슈티컬즈, 엘엘씨 Compositions and methods of treating cell proliferation disorders
US8399489B2 (en) 2005-02-18 2013-03-19 Astrazeneca Ab Antibacterial piperdine derivatives
CN101595084B (en) 2006-06-29 2013-01-02 金克斯医药品有限公司 Biaryl compositions and methods for modulating a kinase cascade
US7935697B2 (en) 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
US7939529B2 (en) 2007-05-17 2011-05-10 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
AU2008310097B2 (en) 2007-10-09 2013-05-16 Merck Patent Gmbh Pyridine derivatives useful as glucokinase activators
JP5637855B2 (en) 2007-11-08 2014-12-10 ザ ジェネラル ホスピタル コーポレイション Methods and compositions for the treatment of proteinuria
KR101752515B1 (en) 2009-07-24 2017-06-29 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Methods and compositions for treating and preventing disease associated with avb5 integrin
WO2011129936A2 (en) 2010-04-16 2011-10-20 Kinex Pharmaceuticals, Llc Compositions and methods for the prevention and treatment of cancer
JP6499076B2 (en) 2012-08-30 2019-04-10 アセネックス インコーポレイテッド N- (3-Fluorobenzyl) -2- (5- (4-morpholinophenyl) pyridin-2-yl) acetamide as a Protein Tyrosine Kinase Modulator
HUE063437T2 (en) 2013-09-24 2024-01-28 Fujifilm Corp Pharmaceutical composition of a nitrogen-containing compound or salt thereof, or metal complex thereof
JP6769963B2 (en) 2014-08-29 2020-10-14 ティエエッセ ファルマ ソチエタ レスポンサビリタ リミタータ Inhibitor of α-amino-β-carboxymuconic acid semialdehyde decarboxylase

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654306A (en) * 1970-01-26 1972-04-04 Robins Co Inc A H 5-azaspiro(2.4)heptane-4 6-diones
IL99537A (en) 1990-09-27 1995-11-27 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical compositions containing them
GB9202792D0 (en) 1992-02-11 1992-03-25 British Bio Technology Compounds
JPH07505647A (en) 1992-04-10 1995-06-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Heterocyclic compounds and their use in the treatment of type 2 diabetes
GB9311282D0 (en) * 1993-06-01 1993-07-21 Rhone Poulenc Rorer Ltd New compositions of matter
GB9315148D0 (en) 1993-07-22 1993-09-08 Smithkline Beecham Plc Novel compounds
US5665754A (en) * 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
DE4408082A1 (en) 1994-03-10 1995-09-14 Hoechst Ag Substituted propane derivatives, process for their preparation and the use of the compounds for the treatment of diseases
AU701776B2 (en) 1994-05-27 1999-02-04 Merck & Co., Inc. Compounds for inhibiting osteoclast-mediated bone resorption
US5710171A (en) * 1995-05-24 1998-01-20 Merck & Co., Inc. Bisphenyl inhibitors of farnesyl-protein transferase
CA2176854A1 (en) 1995-06-07 1996-12-08 Daniel J. Keavy N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics
GB9511694D0 (en) 1995-06-09 1995-08-02 Fujisawa Pharmaceutical Co Benzamide derivatives
DE19536891A1 (en) 1995-10-04 1997-04-10 Basf Ag New amino acid derivatives, their production and use
IT1276153B1 (en) * 1995-11-17 1997-10-27 Roberto Pellicciari GLYCINE DERIVATIVES WITH ANTAGONIST ACTIVITY OF METABOTROPIC GLUTAMATE RECEPTORS
ATE204857T1 (en) 1996-03-29 2001-09-15 Searle & Co META-SUBSTITUTED PHENYLENDER DERIVATIVES AND THEIR USE AS ALPHAVBETA3 INTERGRIN ANTAGONISTS OR INHIBITORS
CA2250695A1 (en) * 1996-03-29 1997-10-09 G.D. Searle & Co. Cyclopropyl alkanoic acid derivatives
DE69713582T2 (en) 1996-03-29 2003-01-09 Searle & Co Cinnamic acid derivatives and their use as integrin antagonists
US6121288A (en) 1996-11-08 2000-09-19 Nippon Chemiphar Co., Ltd. Visceral fat lowering agent
CA2277273C (en) 1997-01-17 2008-03-25 Merck & Co., Inc. Integrin antagonists
JPH10287634A (en) 1997-04-11 1998-10-27 Otsuka Pharmaceut Co Ltd Benzene derivatives
EP1061921A4 (en) 1998-03-10 2005-03-30 Smithkline Beecham Corp Vitronectin receptor antagonists
UA71586C2 (en) 1998-12-04 2004-12-15 Smithkline Beecham Corp A vitronectin receptor antagonist
IL143901A0 (en) 1998-12-23 2002-04-21 Searle & Co Use of cyclooxygenase-2- inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia
EP1177187B1 (en) 1999-04-28 2007-07-25 Sanofi-Aventis Deutschland GmbH Di-aryl acid derivatives as ppar receptor ligands
ATE281433T1 (en) * 1999-05-05 2004-11-15 Aventis Pharma Ltd SUBSTITUTED PYRROLIDINES AS CELL ADHESION INHIBITORS
DE19939980A1 (en) 1999-08-24 2001-03-01 Merck Patent Gmbh Inhibitors of the integrin alphavbeta¶3¶
DE19939981A1 (en) 1999-08-24 2001-03-01 Merck Patent Gmbh New inhibitors of the integrin alphavß3

Also Published As

Publication number Publication date
AR030701A1 (en) 2003-09-03
EP1289960A2 (en) 2003-03-12
PE20020665A1 (en) 2002-08-14
US6949578B2 (en) 2005-09-27
US20040259869A1 (en) 2004-12-23
WO2001096307A3 (en) 2002-08-15
US20020077321A1 (en) 2002-06-20
WO2001096307A2 (en) 2001-12-20
US6900232B2 (en) 2005-05-31
UY26780A1 (en) 2002-01-31
JP2004525069A (en) 2004-08-19

Similar Documents

Publication Publication Date Title
AU2001269821A1 (en) Cycloalkyl alkanoic acids as integrin receptor antagonists
AU2001269876A1 (en) Heteroarylalkanoic acids as integrin receptor antagonists
AU2003299807A1 (en) Heteroarylalkanoic acids as integrin receptor antagonists
AU2001294547A1 (en) Substituted urea neuropeptide y y5 receptor antagonists
AU7315800A (en) Mch antagonists
AU2002210782A1 (en) Amide derivatives as nmda receptor antagonists
AU2001250205A1 (en) Prostaglandin d2 receptor antagonists
AU2002341834A1 (en) Antagonists
EP1254116A4 (en) Alpha v integrin receptor antagonists
AU2001231730A1 (en) Piperidyl carboxylic acids as integrin antagonists
EP1252162A4 (en) Alpha v integrin receptor antagonists
PL356990A1 (en) Isoxazolecarboxamide derivatives as alpha1-adrenergic receptor antagonists
AU2001234741A1 (en) Integrin antagonists
AU2001290772A1 (en) Alpha v integrin receptor antagonists
AU2541000A (en) Beta-phenylalanine derivatives as integrin antagonists
AU2441801A (en) Urotensin-ii receptor antagonists
AU6990000A (en) Novel integrin receptor antagonists
AU9259801A (en) Alpha v integrin receptor antagonists
AU2002220598A1 (en) Beta-amino acid derivatives as integrin receptor antagonists
AU6221201A (en) Propanoic acid derivatives as integrin receptor antagonists
AU2002226048A1 (en) Urotensin-ii receptor antagonists
AU2002239506A1 (en) Urotensin-ii receptor antagonists
AU2001265866A1 (en) Cyclic carboxylic acids as integrin antagonists
AU2001293131A1 (en) Hydroxy acid integrin antagonists
AU2673201A (en) Alpha-arylethylpiperazine derivatives as neurokinin antagonists